Retatrutide is an investigational triple-agonist injectable medicine being studied to support weight loss and improve metabolic health. It is designed to act on three hormone receptors — GLP-1, GIP and glucagon — which may help reduce appetite, enhance energy use and support blood sugar control. Retatrutide is undergoing Phase 3 clinical trials and is not yet approved or available for prescribing in the UK.
the items you wish
to order
by our qualified
prescriber
to your door step
Please use the options provided to make your final selection.
Select your preferred options and see the best price
| Pack | Price (£) | ||
|---|---|---|---|
| - | - | 1 | 0.00 |
It looks like you missed filling in questions from the last consultation.Click Here to submit your response.
Retatrutide is an investigational weight-loss and metabolic medicine being developed by Eli Lilly. Unlike current GLP-1 treatments, Retatrutide targets three hormone receptors — glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon — which together may support reduced appetite, slower digestion, improved glucose control and increased energy use.
Retatrutide’s triple-agonist action helps regulate several aspects of metabolism and appetite. Activation of GLP-1 and GIP receptors helps control hunger and improves the body’s response to food, while glucagon receptor engagement may increase calorie burning and fat use. This combined effect is why Retatrutide is sometimes referred to in research as a “triple” hormone therapy.
Early clinical research has shown significant weight loss results with Retatrutide. In Phase 2 trials, participants on higher doses experienced average weight losses of more than 20% of body weight over 48 weeks, with a high proportion achieving large reductions in weight. Phase 3 TRIUMPH-4 topline results have also been positive, showing substantial weight loss and additional benefits in adults with conditions such as overweight or obesity.
Retatrutide is currently being evaluated in multiple Phase 3 clinical trials globally, including studies comparing it with other treatments and examining long-term safety and effectiveness. These Phase 3 studies will provide crucial data to support future regulatory submissions.
Retatrutide is not yet approved in the UK and remains in clinical development. It is expected that clinical trial results from 2026 could support regulatory submissions, and full UK approval — if granted — may follow in 2027 or later. Until then, it cannot be legally prescribed or supplied in clinical practice.
Retatrutide is an investigational weight-loss and metabolic medicine being developed by Eli Lilly. Unlike current GLP-1 treatments, Retatrutide targets three hormone receptors — glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon — which together may support reduced appetite, slower digestion, improved glucose control and increased energy use.
Retatrutide’s triple-agonist action helps regulate several aspects of metabolism and appetite. Activation of GLP-1 and GIP receptors helps control hunger and improves the body’s response to food, while glucagon receptor engagement may increase calorie burning and fat use. This combined effect is why Retatrutide is sometimes referred to in research as a “triple” hormone therapy.
Early clinical research has shown significant weight loss results with Retatrutide. In Phase 2 trials, participants on higher doses experienced average weight losses of more than 20% of body weight over 48 weeks, with a high proportion achieving large reductions in weight. Phase 3 TRIUMPH-4 topline results have also been positive, showing substantial weight loss and additional benefits in adults with conditions such as overweight or obesity.
Retatrutide is currently being evaluated in multiple Phase 3 clinical trials globally, including studies comparing it with other treatments and examining long-term safety and effectiveness. These Phase 3 studies will provide crucial data to support future regulatory submissions.
Retatrutide is not yet approved in the UK and remains in clinical development. It is expected that clinical trial results from 2026 could support regulatory submissions, and full UK approval — if granted — may follow in 2027 or later. Until then, it cannot be legally prescribed or supplied in clinical practice.
|
|
|
|
|
*% of people losing more than 5% of body weight.
No, Retatrutide is not available for weight loss in the UK. It is still in Phase 3 clinical trials and has not yet been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or other regulatory bodies. Because of this, Retatrutide cannot currently be prescribed or supplied through NHS or private clinics.
In clinical trials, Retatrutide has been given as a once-weekly subcutaneous injection, similar to other injectable weight-loss medicines such as Wegovy or Mounjaro. The dosing schedule may vary during trials, often starting low and increasing over time to help reduce side effects.
Clinical trial results so far have shown that Retatrutide can produce significant weight loss. In some Phase 2 studies, average weight losses at higher doses exceeded 24% over 48 weeks, with a substantial percentage of participants achieving at least 15% body weight reduction. Phase 3 results indicate continued robust weight loss outcomes with Retatrutide.
Because Retatrutide is still under investigation, the full side-effect profile has not been established. However, early trial data suggest that common side effects are similar to those seen with other injectable weight-loss therapies, including nausea, diarrhoea, constipation and vomiting. Full safety assessments will be completed as trials progress.
Retatrutide differs from other approved weight-loss injections such as Mounjaro and Wegovy because it targets three hormone receptors, rather than one or two. This triple hormone receptor action may lead to greater weight loss, although direct comparisons in head-to-head clinical trials are still limited. Research suggests it may offer additional metabolic benefits beyond appetite suppression alone.
Answer a few questions on your health and your fitness goals.
Our clinicians will review your clinical questionnaire to make sure treatment is right for you.
Once approved, you will access our wealth of experience and resources curated by our team and begin your clinical weight loss journey.
Start your weight loss journey heading in the right direction. Our team are here to help. Whether you’re unsure about which medicine is right for you or need help navigating the world of weight loss drugs, our team are on hand to help you make the right decision. We can put you in touch with one of our experienced weight loss clinicians so you can be sure you’re making the best decision with the most accurate information.
To get in touch, contact our Customer Service team on 0800 978 8956 or email [email protected].
Authored on : March 13 2026
HARMINDER ‘HARMY’ KAUR
BSc(hons) Pharmacy
GPhC Number: 2061107
Reviewed on : March 13 2026
GURDEV SEHMI
BSc Pharm, MRPharmS, Independent Prescriber, Superintendent Pharmacist, Clinical Lead
2050925
My Weight Loss Journey with Pharmacy Planet. My name is Michelle, and for as long as I can remember, my weight has been something I struggled with. It affected my confidence, my health, and my overall well-being. I had tried countless diets, exercise ...
My name is Natalie, and for most of my adult life, I’ve struggled with my weight. I’ve tried everything you can imagine—Weight Watchers, Slimming World, calorie counting, Atkins, and even the Cambridge Diet. Some worked for a short time, but nothing ever .....
My name is Linda, and my weight loss journey has been a long and difficult one. I have struggled for years, trying various methods, from Weight Watchers to calorie counting and even gym memberships. Unfortunately, none of these ever provided ....
My Weight Loss Journey with Wegovy and Pharmacy Planet. Losing weight has never been an easy feat for me. I tried all options I had available which were the usual contenders—personal trainers healthy eating, and even strict calorie counting. After all my best ...
For years, trying to lose weight felt impossible. As a woman over 35 navigating losing weight in perimenopause, I’d tried everything—strict diets, intense workouts, even weight loss massages—but nothing worked. Finding it difficult to lose weight became ....
the items you wish to order
by our qualified prescriber
to your door step
